Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J Risperdal Off-Label Settlement Includes Exec Pay Recoupment Provision

This article was originally published in The Pink Sheet Daily

Executive Summary

Janssen subsidiary pleads guilty as part of $2.2 billion deal that also requires audits of sales rep compensation.


Related Content

AmerisourceBergen Settlement On Injectable Drug Repackaging Includes Forfeiture Of Exec Pay
Pharma Deals With The DOJ
J&J Challenges Risperdal Penalty As First Amendment Violation
Legal, PR Efforts Ramp Up To Target J&J On Vaginal Mesh Device Issues
FDA Warning Letter Is Inadmissible Hearsay, Arkansas Supreme Court Says In Tossing J&J Judgment
FDA Generic Labeling Reg Could Fuel Suits Against Brands As Well
Par’s Off-Label Plea Deal Includes Clawback For Execs’ Pay In Case Of Future Misconduct
Risperdal Marketing Settlement Prevents Reprint Distribution Without sNDA
GSK’s DoJ Settlement Requires Execs To Forfeit Bonuses If Misconduct Occurs
Topamax "Doctor For A Day" Program Drove Off-Label Settlement


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts